Gemini said

The Novo Nordisk Foundation is one of the world’s most unique corporate structures. It serves as both a "shield" for the company and a "motor" for global scientific research.

Here is a breakdown of how this ownership model works and why it’s currently making headlines.

---

1. The Power Structure: Voting vs. Value

The company uses a dual-class share system that ensures the foundation retains absolute control, even if it owns less than half of the total company value.

• A-Shares (Control): These are held exclusively by the Foundation (via its investment arm, Novo Holdings). While they represent only about 28% of the capital, they carry 77% of the voting rights.

• B-Shares (Money): These are the shares you buy on the stock market (NYSE: NVO). They provide the dividends and growth but very little say in how the company is run.

• The Benefit: This prevents "hostile takeovers." No matter how much money a competitor or an activist investor has, they cannot buy Novo Nordisk because the Foundation's charter forbids it from ever selling its control.

2. The "Shield" Mentality

Because the Foundation doesn't have to answer to Wall Street’s pressure for "quarterly profits at all costs," Novo Nordisk can operate on a 10-year planning cycle.

• Long-term Research: This is why they were able to spend decades and billions of dollars developing GLP-1 drugs (like Ozempic) when other companies might have abandoned the research due to slow initial returns.

• Stability: The company is effectively immune to the "boom and bust" cycles that plague other tech and pharma giants.

3. The World’s Largest Philanthropic Force

In 2026, the Novo Nordisk Foundation has become one of the wealthiest charitable organizations in existence—frequently rivaling or exceeding the Bill & Melinda Gates Foundation in annual grant payouts.

• Where the money goes: Since the Foundation is the majority owner, a massive portion of the profits from every box of Ozempic sold worldwide flows directly into the Foundation's coffers.

• 2026 Strategy: The Foundation recently announced a DKK 5.5 billion (€736 million) initiative to fund European biotech startups through 2035. They are moving beyond just "healthcare" into:

  • Planetary Health: Carbon capture and sustainable agriculture.

  • Quantum Computing: Funding the "Novo Nordisk Foundation Quantum Computing Programme" to speed up drug discovery.

  • Education: Massive grants for STEM education across the Nordic region.

4. The "Novo Holdings" Investment Arm

The Foundation doesn't just sit on the money. It operates a subsidiary called Novo Holdings, which acts like a massive private equity firm.

• They reinvest the "excess" profits from Novo Nordisk into over 160 other companies globally.

• This creates a "Life Science Ecosystem" where Novo Nordisk’s success fuels the next generation of medical breakthroughs, which the Foundation then also owns a piece of.

---

The "Irony" of Growth: A major debate has emerged in Denmark. The Foundation is now so wealthy that it is struggling to find enough high-quality scientific projects to "spend" its money on without overheating the Danish research sector. This has forced the Foundation to pivot toward massive international projects in the US and Asia.